Vir Biotechnology and Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors October 20, 2026
VS-7375 Demonstrates 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) October 20, 2026
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer October 20, 2026
GOBLET Ph 1/2 study Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in H1 2027 October 20, 2026
Data from FURTHER Ph 1b (FURMO-002) of firmonertinib in 1L EGFR PACC-mutant NSCLC published in Cancer Cell October 20, 2026
FDA granted Fast Track designation to QTX3034 + cetuximab for KRASG12D-mutant CRC, with or without FOLFOX chemotherapy October 20, 2026
Hansoh Pharma Announces Strategic Collaboration and License Agreement With Roche to Advance Novel ADC Portfolio October 20, 2026
Positive Ph 2 Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic CRC Announced October 20, 2026
RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer October 20, 2026
Alentis and PinotBio announce collaboration to develop next-generation ADCs targeting claudin-1 October 20, 2026
Adlai Nortye Enters Clinical Collaboration with Lilly and Merck KGaA to Evaluate Combination of AN4035 and Cetuximab October 20, 2026
NUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology Pipeline October 20, 2026
First Patient Dosed in Hong Kong Clinical Trial of PLT012 for Liver Cancer Expansion October 20, 2026
Efficacy Data presented from Ph 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy October 20, 2026
Ph 3 Data Shows 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® + BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors October 20, 2026
FDA cleared IND application for LB2501 for R/R B-cell malignancies, including B-cell NHL October 20, 2026
FDA grants Fast-Tracks designation to Invikafusp Alfa for Previously Treated TMB-High Solid Tumors October 20, 2026
NDA resubmitted to FDA for Camrelizumab + Rivoceranib in 1L Unresectable or Metastatic HCC October 20, 2026
FDA Expands ANKTIVA® Approval for BCG-Unresponsive NMIBC to Cover Both Papillary and CIS Disease October 20, 2026
Jemperli (dostarlimab) approved in US for adults with MSI-H/dMMR locally advanced rectal cancer October 20, 2026
